Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.

MLA

Suguru Harada, et al. “Superior Antitumor Activity of Trastuzumab Combined with Capecitabine plus Oxaliplatin in a Human Epidermal Growth Factor Receptor 2-Positive Human Gastric Cancer Xenograft Model.” Molecular & Clinical Oncology, vol. 3, no. 5, Sept. 2015, pp. 987–94. EBSCOhost, https://doi.org/10.3892/mco.2015.609.

APA

Suguru Harada, Mieko Yanagisawa, Saori Kaneko, Keigo Yorozu, Kaname Yamamoto, Yoichiro Moriya, & Naoki Harada. (2015). Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Molecular & Clinical Oncology, 3(5), 987–994. https://doi.org/10.3892/mco.2015.609

Chicago

Suguru Harada, Mieko Yanagisawa, Saori Kaneko, Keigo Yorozu, Kaname Yamamoto, Yoichiro Moriya, and Naoki Harada. 2015. “Superior Antitumor Activity of Trastuzumab Combined with Capecitabine plus Oxaliplatin in a Human Epidermal Growth Factor Receptor 2-Positive Human Gastric Cancer Xenograft Model.” Molecular & Clinical Oncology 3 (5): 987–94. doi:10.3892/mco.2015.609.